ArticleBiochemical and biophysical research communications2004
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine.
Article in Biochemical and biophysical research communications, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 279 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
279 citing papers in PubMed, 1 synthesis or guideline pooled it, 428 citations in OpenAlex.
- COVID diagnostics by molecular methods: A systematic review of nucleic acid based testing systems.Indian journal of medical microbiology · 2021Pooled it
- Trial
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.The New England journal of medicine · 2020Trial
- Trial
- Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccination.NPJ vaccines · 2026Article
- A novel nanoparticle vaccine, based on S1-CTD, elicits robust protective immune responses against porcine deltacoronavirus.Journal of virology · 2025Article
- Review
- Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19.Frontiers in immunology · 2025Article
- Bivalent circular RNA vaccines against porcine epidemic diarrhea virus and transmissible gastroenteritis virus.Frontiers in immunology · 2025Article
- Receptor-binding domain-associated serotypes of SARS-CoV-2.Emerging microbes & infections · 2024Article
- Improvement of RBD-FC Immunogenicity by Using Alum-Sodium Alginate Adjuvant Against SARS-COV-2.Influenza and other respiratory viruses · 2024Article
- Beyond COVID-19: the promise of next-generation coronavirus vaccines.Npj viruses · 2024Review
- Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS-CoV-2 neutralization.Immunity, inflammation and disease · 2024Article
- Intranasal boosting with RBD-HR protein vaccine elicits robust mucosal and systemic immune responses.Genes & diseases · 2024Article
- The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI.Brain and behavior · 2024Article
- Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2.Frontiers in immunology · 2024Article
- Covid-19 Prevention and Treatment by Targeting Fc-fusion Proteins: An Experience to Fight Emerging Diseases.Current molecular medicine · 2024Review
- Neutralization of Different Variants of SARS-CoV-2 by a F(ab')2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain.Antibodies (Basel, Switzerland) · 2023Article
- Mapping immunological and host receptor binding determinants of SARS-CoV spike protein utilizing the Qubevirus platform.The Journal of biological chemistry · 2023Article
- A tool for the cheap and rapid screening of SARS-CoV-2 variants of concern (VoCs) by Sanger sequencing.Microbiology spectrum · 2023Article
219 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (CoV), a type I transmembrane envelope glycoprotein, consists of S1 and S2 domains responsible for virus binding and fusion, respectively. The S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. Here we show that a recombinant fusion protein (designated RBD-Fc) containing 193-amino acid RBD (residues 318-510) and a human IgG1 Fc fragment can induce highly potent antibody responses in the immunized rabbits. The antibodies recognized RBD on S1 domain and completely inhibited SARS-CoV infection at a serum dilution of 1:10,240. Rabbit antisera effectively blocked binding of S1, which contains RBD, to ACE2. This suggests that RBD can induce highly potent neutralizing antibody responses and has potential to be developed as an effective and safe subunit vaccine for prevention of SARS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.